

19 July 2017

Australian Securities Exchange Exchange Centre 20 Bridge Street Sydney NSW 2000

Alcidion to Present at The Small Companies Forum

Alcidion Group Limited (ASX:ALC) today announced that it will present at the Small Companies Forum in Adelaide on the 19th July 2017.

Executive Chairman and CEO, Mr. Raymond Blight will present on behalf of Alcidion. Updating the group on the latest developments within the company and its first year as a listed company.

Event Details

Adelaide Event

Date: Wednesday 19th July 2017

Alcidion presenting at 6:50 pm

Venue: Ground Floor, 226 Greenhill Road

Eastwood, SA 5063

A copy of the presentation in included as an Appendix to this announcement.

ENDS



For further information, please contact:

Nathan Buzza, Executive Director Ph: +61 (0) 488862222 Alcidion Group Limited nathan.buzza@alcidion.com Ray Blight, Chief Executive Officer Ph: +61 (08) 8208 4600 Alcidion Group Limited ray.blight@alcidion.com

About Alcidion

Alcidion Group Limited (ASX:**ALC**) is a publically listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion's solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion's focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Group Limited 2017. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies



ALCIDION

DISCLAIMER

Disclaimer

This presentation has been prepared by Alcidion Group Limited (the "Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other Jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.





ASX Ticker

Market Capitalisation

Ownership

Share Price

Share Range (12 Months)

Share Volume (12 Months)

Cash on hand

Enterprise Value

Shares on Issue

Employees

Revenues FY16

Cumulative R&D Investment

Contingent Share Rights

11,827,957 Shares on achieving \$10m in TTM revenue by 29/2/2018 and; 15,053,763 Shares on achieving \$15m in TTM revenue within 29/2/2019.

All financial data has been rounded as of 31 March 2017 Equity data accurate as of 17 July 2017

ALC

\$42.54 million

38% Founders

14% BlueSky Private Equity

5% Owned by Employees

7.0c

 $3.50c \rightarrow 14.50c$

145m Shares (TTM)

\$5.65 million

\$42 million

608 million

24 x FTE

\$4 million

\$20.8 million



WHY IS DIGITAL HEALTH SUCH AN EXCITING INVESTMENT OPPORTUNITY?

- The global population is aging, resulting in a dramatic and unparalleled service increase in complex patients with multiple co-morbidities.
- New therapies, treatment technologies and medical devices are contributing to escalating service demand.
- As an indicator of demand growth, US spend on healthcare is 18% of GDP (over \$USD3 trillion dollars pa), which if unchecked, will grow to 37% by 2050.

Service demand is growing rapidly





WHY IS DIGITAL HEALTH SUCH AN EXCITING INVESTMENT OPPORTUNITY?

- The US Patient Protection & Affordable Care in 2010, mandated that all US hospitals upgrade their Clinical Information Systems.
- This HITECH Act stipulates that healthcare providers must demonstrate the meaningful use of health IT by 2016 or face a reduction in Medicare reimbursements.
- Close on \$40billion spent in US in digitising patient data via Electronic Health Records and other systems.
- Globally, including in ANZ, patient data is rapidly going digital.

Health is rapidly digitising, after a slow start compared to other industries





WHY IS DIGITAL HEALTH SUCH AN EXCITING INVESTMENT OPPORTUNITY?

- The Global Governments are allocating funds to Digital Health:
 - The United States government has set aside more than \$USD20 billion in stimulus funds to implement Electronic Health Records.
 - The United Kingdom has allocated £4 billion to transition the National Health Service into a paperless environment.
- Global expenditure on Healthcare IT is expected to grow to \$USD114.75 billion by 2019, from \$USD84 billion in 2014 (Source: Health Analytics).

Forward spending plans on health care digitisation are huge





WHERE DOES ALCIDION FIT

Service demand is growing rapidly

Health is finally digitising, at an accelerating rate

Forward spending plans on digital health are huge

Where does Alcidion fit in this exciting global market for digital health?





AN UNACCEPTABLE TRUTH

- The third largest killer of US citizens (2015 Survey), after cancer and heart disease is:
 Avoidable errors that occurred during the delivery of healthcare services
- An unacceptable fact that equally applies across other advanced western health care systems

Patient deaths occur because emerging clinical risk(s) go undetected, and unmanaged

• There is a digital health market niche around clinical risk detection, and clinical decision support to mitigate the patient risk.





ALCIDION'S MARKET POSITION?


- Health informatics technology:
 better, faster decisions to save lives
- Adaptable, easy to use software to:
 detect emerging patient clinical risk
 provide clinical decision support guidance
- Supporting high performance health care:
 safe, fast, efficient and effective care
 high patient and staff satisfaction






WHERE WE HAVE COME FROM









ALCIDION GOING FORWARD?

Why


Better, faster decisions to save lives

How

Detection of clinical risk, guidance re clinical decision support, and relevant, actionable, information made visible when/where the care team needs it.

What

Smart, adaptable, healthcare software that care teams love to use.





EXECUTIVE DIRECTORS



Chief Medical Officer Prof. Malcolm Pradhan

- Formal qualifications in medicine complimented by a PhD in Medical Informatics from Stanford University.
- Founding fellow of the Australasian College of Health Informatics.
- Associate Dean of IT & Director of Medical Informatics at the University of Adelaide.
- Clinical Lead within the Australian Government's National e-Health Transition Authority.

Non-Executive Director Mr. Brian Leedman

- Formal qualifications include Formal qualifications include Former founder & CEO of a Bachelor of Economics and a MBA.
- Co-Founder of Resapp Health (ASX:RAP)
- Co-Founder of Oncosil Medical (ASX:OSL).
- Co-Founder of Imugene (ASX:IMU).
- · WA Chairman of AusBiotech.
- Previously Marketing Manager at Ernst & Young.

Chief Executive Officer Mr. Ray Blight

- a Bachelor of Technology. Bachelor of Economics and a MBA.
- Former CEO of the South Australian Health Commission and Chair of the Health Ministers' **Advisory Council**
- Consultant to the World Bank.
- Chairs the University of SA IT & Mathematical Sciences Advisory Board.



- Clinical Middleware provider. Commtech Wireless.
- EY "Entrepreneur of the Year".
- BRW in the Fast100 for three consecutive years.
- Western Australia IT & telecommunications Life Time achievement Award for contribution to the IT community.
- Previously the second largest shareholder of Azure Healthcare (ASX:AZV).



Mr. Nick Dignam

- Formal qualifications include a Bachelor of Commerce. Bachelor of Law and a Masters of Applied Finance.
- Investment Director of BlueSky (ASX:BLA), a listed alternative asset manager with \$1.7b of assets under management.
- Responsible for originating new investment opportunities, working with portfolio companies to deliver growth and managing exit processes.
- Joined Blue Sky from Catalyst Investment.



HIGHLIGHTS PAST YEAR

- Listed Alcidion on the ASX on February 29 2016, with \$7m in cash, with minimal debt.
- Posted two consecutive cashflow positive quarters for Q1 and Q2 in FY17, with total cash of \$5.65m (plus R&D Tax Provision of \$782k)
- Commenced our commercialiation strategy, which in broad terms will see the Alcidion Sales Team systematically engage the continuum of Australian and New Zealand healthcare.
- Executed a \$2.35 MoU with Western Health, signifying the transition of our Patient Flow and Bed Management applications from Pilot Site to commercial utilization.
- Signed an agreement with Calvary Health to assist the organization with streamlining clinical coding and patient data across their facilities.
- Signed a \$1.6m agreement with the MidCentral District Health Board in New Zealand for Patient Flow, Bed Management and Hospital Operations Centre solution.





HIGHLIGHTS PAST YEAR

- Invested \$1.5m developing a Computerized Physician Order Entry (CPOE) platform, in the form of a Best Practice Pathology Ordering product that automates the electronic ordering of pathology for ED physicians.
- Tasmania's Northern Integrated Care Service went live with Alcidion's Miya iReferrals.
- Deployed our Critical Test Results Management Platform across the Northern Territory.
- Announced that our strategic partner, FUJIFILM had secured multiples sales of our intelligent Cardiovascular Information System (iCVIS).
- Integrated into the Cerner EMR Platform Alcidion's first deployment in NSW.
- Brought two new external products into the offering:
 - Miya Smartpage: cloud software for clinical communication and collaboration
 - Miya iScheduler: advanced appointments scheduling, electronic referrals, wait list management and telehealth scheduling















